Overview Objectives / Main projects covered by AMED
Medical R&D in Japan was seen as suffering from the problems of lacking a system that provides sufficiently seamless funding, from basic research to practical application, and lacking a system that adequately implements clinical studies / trials, causing discovery of new drugs to take too long. In order to deal with these issues, the Japan Agency for Medical Research and Development aims to act as a 'control tower' that directs integrated research, from basic research to practical application. And since Japan is projected to become the world's first ultra-aging society, AMED aims to achieve the world's healthiest and longest-living people by creating the world's most advanced medical technologies and services, and also aims to become a pillar of Japan's economy by fostering medicine, drugs, and medical devices as strategic industries.
Promotion of R&D in the six integrated projects defined in the 2nd Healthcare Policy and medium- to long-term plan
- Establish six “Integrated Projects”centered on modalities, and under the Program Director (PD), the projects of related ministries and agencies will be coordinated, and will be centrally promoted from basic to practical application.
- Disease research will be promoted across the integrated projects so that it can be managed flexibly by the coordinators of each disease.
- Implement a technical approach with clearly defined development objectives such as “prevention, diagnosis, treatment, prognosis, QOL”, with a focus on extending healthy longevity.
Main projects covered by AMED
Project for Advanced Drug Discovery and Development
This project conducts pharmaceutical R&D taking into account the characteristics and properties of modalities in areas ranging from target identification to clinical research in order to promote the practical application of drugs to address high medical needs. For example, essential R&D such as the development of new modalities, each modality’s design, compound optimization, activity assessment, evaluation methods of efficacy/safety, and manufacturing technology is covered by this project. In addition, it aims to realize innovative drugs by utilizing technologies and knowledge about various modalities for diseases from a cross-sectional perspective. It also focuses on establishing the infrastructure to support drug discovery, including technologies for drug design, compound libraries, and sharing of analytical tools.
Project for Medical Device and Healthcare
This project supports R&D of medical devices/systems and healthcare, which integrated AI/IoT technologies, measurement technologies, robotics technologies etc. in, aiming improved diagnosis, treatment and prevention of diseases, and the improved QOL of the elderly.
Project for Regenerative / Cellular Medicine and Gene Therapies
This project supports basic research on regenerative medicine/cell therapy, non-clinical and clinical research, development of foundational manufacturing technology, research utilizing disease-specific iPSCs, and establishment of necessary foundational structures for research, as well as R&D in the field of gene therapy.
Project for Genome and Health Related Data
For realization of genome and personalized medicines, this project promotes to activate some infrastructures and utilizations based on genome and its relating data, and supports the medical R & D to contribute various disease onset, prevention from serious illness, diagnosis, and therapy, which are corelated to between genetic mutation and polymorphism and various disease onset, overlooking a personal life-stage. Moreover, this project will support various study for implementation of a new diagnosis and intervention which are utilized medical data (e.g., medical registries) and for collection of an intangible (knowledge/experience) medical technology and correction of its relating system. Therefore, AMED will progress the data-sharing based on this project.
Project for Basic Medical Research
This project supports basic R&D to better understand various functional aspects of life phenomena such as brain functionality, immunity, and aging, as well as to elucidate disease mechanisms in various diseases. Results will be linked with clinical R&D and other integrated projects, while R&D that incorporates clinical issues will be supported.
Project for Seeds Development and Research Base
This project supports basic research and international joint research to create and develop bases combining different fields, modalities and innovative seeds for creation of new modalities. It also promotes development of systems to discover/transfer seeds and conduct high-quality clinical research & trials, establishment of a base of reverse translational research & empirical research in translational research among support centers and core clinical research hospitals.
This project supports R&D conducted through industry-government-academia collaboration and promotes the development of an environment for collaboration by using government investment to create innovative drugs and medical devices, etc.
Moonshot Research and Development Program
This program aims to create the breakthrough innovation from Japan. The goal of our Moonshot program is to promote challenging research and development based on revolutionary concepts that are not merely extensions of conventional technologies. From the perspective of future society, this program conducts R&D focused on difficult social tasks but expected to offer a significant impact.
Programs relating to the Strategy for Strengthening the Vaccine Development and Production System (SCARDA-related and other programs)
Pursuant to the Strategy for Strengthening the Vaccine Development and Production System (the “Vaccine Strategy”), AMED aims to prepare for infectious disease emergencies and be able to respond to more virulent mutant strains and infectious diseases that could prove to be a threat in the future. Accordingly, AMED boosts the funding capacity for strategically significant research, initiative for world-leading vaccine research and development centers, and promotes the strengthening of the pharmaceutical startup ecosystem.
Last updated 09/09/22